Global Shortage of Visudyne Expected to Ease in 2027 Following New European Supply Chain Approval

The European Medicines Agency (EMA) has announced that the longstanding global shortage of Visudyne (verteporfin), a drug used in ophthalmology, is expected to alleviate in 2027. This follows the establishment of a new European supply chain in July 2026 and the finalization of approvals for new manufacturing sites. The shortage, which began in May 2020 due to reduced manufacturing capacity, led to insufficient supply and controlled distribution. The EMA's approval of these new arrangements is anticipated to restore full supply levels across the EU and end the controlled distribution system.